Victory Square Company Announces Access to Tirzepatide and GLP-1 Injections to its Weight Loss Portfolio
VANCOUVER, British Columbia, May 23, 2024 (GLOBE NEWSWIRE) — Victory Square Technologies Inc. (“Victory Square”) (CSE:VST) (OTC:VSQTF) (FWB:6F6), a company that gives investor access to a portfolio of 25+ innovative companies from around the world in a single stock, is pleased to share that its portfolio company – Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV:NURS)(OTCQB:HYDTF)(FSE:SO6) a mobile clinical network and medical platform which enables flexible, at-home medical services across the United States, is pleased to announce that its over 3,000 nurses, 107 white-label locations and their patients now have access to Tirzepatide through the Hydreight platform and its associated Medical network in over 700 cities across 50 states in the United States.
Related news for (VSQTF)
- Victory Square Technologies Announces Transaction Involving Its Wholly Owned Subsidiary, BlockX
- Victory Square’s GameOn Drives Record $1.85M in Revenue, Reports Profitable Q1
- Victory Square’s XR Immersive Tech Licenses LBVR Platform to Deploy Reality in $4.5M Agreement
- Victory Square Company Hydreight Expands Its “At-Home Blood Testing” Solution with More Tests To All 50 States
- Victory Square Company Provides Corporate Update Reflecting Significant Revenue Growth & Strong Organic Operational Growth